ArticleSeminars in arthritis and rheumatism2026
Clinical characteristics and risk factors associated with objective flares in patients with dermatomyositis.
Article in Seminars in arthritis and rheumatism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundFlares in dermatomyositis (DM) are associated with increased disability, health care utilization, and reduced quality of life. We aim to determine the characteristics and risk factors of flares in patients with DM.
methodsPatients were included if seen at The Johns Hopkins Myositis Center and fulfilled the 2017 EULAR/ACR Classification Criteria for DM. Two authors reviewed all notes and recorded patient symptoms, exams, labs, imaging findings, and medication changes. Objective flare was defined as active disease on exam or ancillary testing that resulted in an increase in immunosuppressive therapy. Characteristics of patients and flares were summarized using descriptive statistics. We assessed the association between patient characteristics and time to first flare using Cox proportional hazards models.
resultsIn this study with 637 patients with DM, rash was the most common finding of flare (75.7%), followed by muscle weakness (58.4%), new/worsening findings on lung function tests and/or imaging (19.0%) and arthritis (12.4%). Over 85% of the patients who reported rash, weakness, dyspnea, joint swelling, dysphagia or fever met the definition of objective flare. Black race and shorter time to diagnosis were associated with increased flare risk. Among patients with DM who experienced an objective flare, only 2-5% had a cancer diagnosis within 6-24-months of flare. In a subset of newly diagnosed patients, 26% had ≥1 flare during follow-up. The incidence rate of flares was 5.1 per 100 person-years. The average time between diagnosis and the first flare was 2.9 years (SD 2.3) ranging between 6.2 months and 10.8 years.
conclusionIn this tertiary care center cohort of DM patients, patient-reported symptoms of increased disease activity were often indicative of objective flare. We identified Black race and shorter time to diagnosis as risk factors for flare. Understanding these factors can inform clinicians about monitoring strategies and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.